Patrick Gilligan marked his first year as chief executive officer of Point32Health, the parent company of Harvard Pilgrim Health Care and Tufts Health Plan, navigating a complex health care landscape marked by rising costs, shifting drug coverage policies, and ongoing market pressures. Under his leadership, the Massachusetts-based insurer has implemented significant cost-containment measures, including restrictions on coverage for GLP-1 weight-loss medications, which have contributed to a notable financial turnaround in early 2026.
Gilligan, who brought experience from both the insurance and health system sectors, took charge amid heightened demand for health care services following the COVID-19 pandemic and escalating pharmaceutical expenses. He attributed much of the financial strain to pent-up demand for medical care delayed during the pandemic and the rapid increase in utilization and pricing of specialty and branded drugs, particularly gene and cell therapies known for their high costs.
GLP-1 drugs, originally prescribed for diabetes management but increasingly used off-label for weight loss, became a focal point last year due to their soaring costs. Point32Health, like several other insurers, narrowed its coverage of these medications chiefly to patients with diabetes, a move that Gilligan said was necessary after initial estimates significantly underestimated the uptake of GLP-1s for weight loss. The company’s operating income rebounded to $86 million in the first quarter of 2026 from a $39 million loss in the same period the previous year.
While acknowledging the difficult nature of limiting benefits, Gilligan emphasized the importance of maintaining affordability for individuals, employers, and the insurer alike. The decision was met with disappointment from affected members, and some employer clients initially questioned the move. Nevertheless, Gilligan indicated the dialogue over coverage of high-cost drugs would continue evolving as health plans balance efficacy and cost.
Despite the positive first-quarter results, Point32Health’s chief financial officer has cautioned that the gains might not extend across the full year or translate into immediate cost savings for members. Gilligan echoed this view, describing 2026 as a transitional year aimed at building toward modest profitability while continuing to focus on operational efficiency and administrative cost reductions.
The company has also faced external challenges, including the reduction of subsidies through the Massachusetts Health Connector, which has led to a decrease in membership across Point32Health and its competitors. This marks a shift away from nearly universal coverage in the state, adding further pressure on the insurer’s financial results.
In addition to adjusting coverage policies, Point32Health undertook significant layoffs during Gilligan’s first year, part of broader efforts to improve competitiveness. While he did not commit to the end of further workforce reductions, Gilligan stressed the importance of ongoing efficiency improvements within the company and among contracted providers to sustain long-term viability in a highly competitive market.
As Point32Health moves forward, the company aims to balance cost management with providing value to members, acknowledging that the evolving landscape of drug pricing and health care demand will require continuous adaptation.